¿La asociación entre covid-19 y diabetes está impulsada por el receptor dpp4?
(Is the association between covid-19 and diabetes driven by the dpp4 receptor?)
Primeras 5 respuestas:
-
The presence of diabetes considerably influences the course of COVID-19 infection, being a risk factor for poor outcomes.
-
Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19.
-
Diabetes affects more than 400 million people worldwide,
-
DPP4 upregulation may be a determinant of COVID-19 disease severity,
-
DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and non-enzymatic immunomodulatory effects.
The presence of diabetes considerably influences the course of COVID-19 infection, being a risk factor for poor outcomes.
... The presence of diabetes considerably influences the course of COVID-19 infection, being a risk factor for poor outcomes. In limited preclinical studies, ACE2 expression was found to be modulated by several players in different tissues. Most of them are largely employed in the treatment of diabetes, such as ...
Ref: COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? [J Endocrinol Invest, 2020-06-03]Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19.
... Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the ...
Ref: cord_uid 5k61tlva SARS-CoV-2 and DPP4 inhibition: Is it time to ... 5k61tlva SARS-CoV-2 and DPP4 inhibition: Is it time to ... Name: title, dtype: object [J Endocrinol Invest, cord_uid 5k61tlva 2020 5k61tlva 2020 Name: publish_time, dtype: object]Diabetes affects more than 400 million people worldwide,
... of current drugs targeted against RAAS and DPP4 to treat or prevent COVID-19-derived vascular complications Diabetes affects more than 400 million people worldwide, thus better understanding of how they are affected by COVID-19 holds an important benefit to ...
Ref: DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? [Frontiers in pharmacology, 2020]DPP4 upregulation may be a determinant of COVID-19 disease severity,
... older individuals and increased plasma DPP4 is a predictor of the onset of metabolic syndrome. DPP4 upregulation may be a determinant of COVID-19 disease severity, which creates interest regarding the use of gliptins in management of COVID-19. Also, knowledge of ...
Ref: cord_uid iml9ig5n COVID-19 and comorbidities: A role for dipepti... iml9ig5n COVID-19 and comorbidities: A role for dipepti... iml9ig5n COVID-19 and comorbidities: A role for dipepti... Name: title, dtype: object [Frontiers in pharmacology, cord_uid iml9ig5n 2020 iml9ig5n 2020 iml9ig5n 2020 Name: publish_time, dtype: object]DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and non-enzymatic immunomodulatory effects.
... circulates in plasma; it is multifunctional with roles in nutrition, metabolism, immune and endocrine systems. DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and non-enzymatic immunomodulatory effects. The importance of DPP4 for the medical community has been highlighted by the approval of ...
Ref: Covid-19 and co-morbidities: a role for Dipeptidyl Peptidase 4 (DPP4) in disease severity? [Journal of diabetes, 2020-05-11]Abstract Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 Covid-19.
... Abstract Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 Covid-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the ...
Ref: SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons? [Diabetes Res Clin Pract, 2020-04-23]We have shown that higher plasma DPP4 is evident in obesity, metabolic syndrome and type 2 diabetes [6] and increases with aging [7] ,
... There is, however, a point worth taking from Iacobellis" remarks. We have shown that higher plasma DPP4 is evident in obesity, metabolic syndrome and type 2 diabetes [6] and increases with aging [7] , all representing significant risk factors for unfavourable COVID-19 outcomes [8] . Thus, increased DPP4 may represent a driver for clinical ...
Ref: COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications [Diabetes Res Clin Pract, 2020-04-23]Diabetes is associated with increased COVID-19 severity and mortality,
... or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COVID-19 severity and mortality, and accumulating evidence suggests that IBTs may favorably alter the clinical course of SARS-CoV-2 infection ...
Ref: Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. [Journal of cardiovascular pharmacology and therapeutics, 2020-07-03]Some primary results have found and discussed the associations between the ACE2 variants and comorbidities like diabetes [41] [42] 45 ].
... the CD4 receptor (C868T) and CCR5-Δ32 have conferred susceptibility and resistance, respectively [52] [53] . Some primary results have found and discussed the associations between the ACE2 variants and comorbidities like diabetes [41] [42] 45 ]. So, based on such findings, the possibility of ACE2 polymorphisms rendering susceptibility or resistance towards ...
Ref: COVID-19 and Diabetes; possible role of polymorphism and rise of telemedicine [Prim Care Diabetes, 2020-08-31]the association between DPP4i and COVID-19 warrants further investigation.
... pemphigoid (29) and inflammatory bowel disease (30) . Given the high number of type 2 diabetic patients involved in the COVID-19 pandemic and the wide use of DPP4i in diabetes, the association between DPP4i and COVID-19 warrants further investigation. ...
Ref: DPP4 inhibition: preventing SARS‐CoV‐2 infection and/or progression of COVID‐19? [Diabetes Metab Res Rev, 2020-04-26]DPP4 has important metabolic and immune functions and is a target for commonly used therapies in T2D.
... MERS-CoV (Middle East respiratory syndrome-related coronavirus) and ACE2 have similar expression profiles in the lung. DPP4 has important metabolic and immune functions and is a target for commonly used therapies in T2D. CONCLUSIONS: Although clinical data supporting an influence of all these drugs on the course of ...
Ref: COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? [J Endocrinol Invest, 2020]DPP4 is the prime receptor for Middle East respiratory syndrome coronavirus responsible for its entry into cell [19] .
... is some data regarding use of dipeptidyl peptidase 4 (DPP4) inhibitors from previous viral epidemics. DPP4 is the prime receptor for Middle East respiratory syndrome coronavirus responsible for its entry into cell [19] . Hence the possibility of DPP4 facilitating the entry of SARS CoV-2 into the cell cannot ...
Ref: cord_uid 4ti8l2ea Diabetes and COVID-19: evidence, current statu... 4ti8l2ea Diabetes and COVID-19: evidence, current statu... Name: title, dtype: object [J Endocrinol Invest, cord_uid 4ti8l2ea 2020-05-13 4ti8l2ea 2020-05-13 Name: publish_time, dtype: object]DPP4 serves as the receptor for MERS-CoV,
... (GLP-1), DPP4 activates T-cells, and upregulates CD86 expression and the NF-κB pathway, thereby promoting inflammation. DPP4 serves as the receptor for MERS-CoV, in the same way as ACE2 is the receptor for SARS-CoV and SARS-CoV2 [50, 51] ...
Ref: The COVID-19 pandemic and diabetes mellitus [Arch Med Sci Atheroscler Dis, 2020-07-21]The CORONADO study showed no association with disease severity of routine therapies for people with diabetes,
... a major role by either favoring disease progression or protecting from development of critical illness. The CORONADO study showed no association with disease severity of routine therapies for people with diabetes, including blockers of the renin-angiotensin system (RAS) and inhibitors of dipeptidyl peptidase-4 (DPP4) [40] , ...
Ref: Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? [Acta Diabetol, 2020-08-31]Upon infection with MERS-CoV, diabetic mice had a prolonged phase of severe disease and delayed recovery that was independent of viral titres.
... dipeptidyl peptidase 4 (DPP4), and type 2 diabetes was induced by administering a high-fat diet. Upon infection with MERS-CoV, diabetic mice had a prolonged phase of severe disease and delayed recovery that was independent of viral titres. Histological examination revealed that diabetic mice had delayed but prolonged systemic inflammation, fewer inflammatory monocyte/macrophages ...
Ref: Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis [Diabetes Metab Syndr, 2020-05-06]Although there is no adequate data with DPP-4Is currently in patients with diabetes with COVID-19,
... Although there is no adequate data with DPP-4Is currently in patients with diabetes with COVID-19, the study by Zhu et al [42] reported that a significantly different proportion of patients with diabetes and COVID-19 were receiving DPP-4Is in a propensity-matched well-controlled arm vs. poorly-controlled arm ...
Ref: Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A Narrative Review [Diabetes Res Clin Pract, 2020-06-11]Incidence and case fatality rate are significantly higher among elderly individuals (age>60 years), type 2 diabetes and hypertension patients.
... more than 200 countries and territories are directly affected by the coronavirus disease-19 (COVID-19) pandemic. Incidence and case fatality rate are significantly higher among elderly individuals (age>60 years), type 2 diabetes and hypertension patients. Cellular receptor ACE2, serine protease TMPRSS2 and exopeptidase CD26 (also known as DPP4) are the ...
Ref: Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human. [Journal of genetics, 2020]Hypertension and Diabetes are the most common comorbid conditions in patients with COVID-19 and has been shown to adversely impact prognosis globally.
... Hypertension and Diabetes are the most common comorbid conditions in patients with COVID-19 and has been shown to adversely impact prognosis globally. It has been shown that hyperglycemia is one of the factors that increases the risk of poor outcomes in these patients . These patients are usually on multiple medications and ...
Ref: Is DPP4 inhibition a comrade or adversary in COVID-19 Infection [Diabetes Res Clin Pract, 2020-05-19]Patients with diabetes mellitus have been reported to be at a high risk of complications from SARS-CoV2 virus infection (COVID-19).
... Patients with diabetes mellitus have been reported to be at a high risk of complications from SARS-CoV2 virus infection (COVID-19). In type 2 diabetes, there is a change in immune system cells, which shift from an anti-inflammatory to a predominantly pro-inflammatory pattern. This altered immune profile may induce important clinical ...
Ref: cord_uid 7ecrjbak Potential role of incretins in diabetes and CO... 7ecrjbak Potential role of incretins in diabetes and CO... Name: title, dtype: object [Diabetes Res Clin Pract, cord_uid 7ecrjbak 2020 7ecrjbak 2020 Name: publish_time, dtype: object]Incidence and case fatality rate are significantly higher among elderly individuals (age > 60 years), type 2 diabetes and hypertension patients.
... more than 200 countries and territories are directly affected by the coronavirus disease-19 (COVID-19) pandemic. Incidence and case fatality rate are significantly higher among elderly individuals (age > 60 years), type 2 diabetes and hypertension patients. Cellular receptor ACE2, serine protease TMPRSS2 and exopeptidase CD26 (also known as DPP4) are the ...
Ref: Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human [J. Genet., 2020]Incidence and case fatality rate are significantly higher among elderly individuals (age > 60 years), type 2 diabetes and hypertension patients.
... more than 200 countries and territories are directly affected by the coronavirus disease-19 (COVID-19) pandemic. Incidence and case fatality rate are significantly higher among elderly individuals (age > 60 years), type 2 diabetes and hypertension patients. Cellular receptor ACE2, serine protease TMPRSS2 and exopeptidase CD26 (also known as DPP4) are the ...
Ref: Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human [J Genet, 2020-06-09]this is the first study that shows an elevated DPP4 expression in naso- and oropharyngeal swabs of COVID-19 patient
... and suggests that ACE2 and DPP4 expression level could act as genomic biomarkers Moreover, at the best of our knowledge, this is the first study that shows an elevated DPP4 expression in naso- and oropharyngeal swabs of COVID-19 patient thus suggesting a functional role of DPP4 in SARS-CoV-2 infections ...
Ref: Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients [Heliyon, 2020]Similar to DPP4 inhibitors, systemic anti-inflammatory effects have been associated with the use of GLP1 RAs in patients with T2D,
... [57] , whereas the once daily preparation of semaglutide for oral administration is forthcoming (www.ema.europa.eu/). Similar to DPP4 inhibitors, systemic anti-inflammatory effects have been associated with the use of GLP1 RAs in patients with T2D, as a consequence of the inhibitory activity on cytokine release, due to their interference with ...
Ref: Potential Benefits and Harms of Novel Antidiabetic Drugs during COVID-19 Crisis [Int J Environ Res Public Health, 2020-05-22]MERS-CoV binds to the receptor-binding domain and interacts with T cells and nuclear factors,
... was identified as a functional receptor for the spike protein of the MERS-Co-V [4] . MERS-CoV binds to the receptor-binding domain and interacts with T cells and nuclear factors, such as NF-jB, highly involved in the pathogenesis of inflammatory disorders. Antibodies directed against DPP4 ...
Ref: COVID-19 and diabetes: Can DPP4 inhibition play a role? [Diabetes Res Clin Pract, 2020-03-26]there is currently no evidence to support clinically meaningful effects on immune function through DPP4 inhibition [14] .
... prescribed ACE inhibitor drugs and angiotensin receptor blockers have been advised to continue taking them [15] . Membrane-associated dipeptidyl peptidase 4 (DPP4) also functions as a coronavirus receptor [33] but there is currently no evidence to support clinically meaningful effects on immune function through DPP4 inhibition [14] . ...
Ref: COVID-19: Impact of and on Diabetes [Diabetes Ther, 2020-06-06]A study in 161 patients with COVID-19 in Wuhan found increased time for viral clearance in patients with diabetes [33] .
... failure seen in severe disease. As discussed, diabetes is associated with poorer outcomes in COVID-19. A study in 161 patients with COVID-19 in Wuhan found increased time for viral clearance in patients with diabetes [33] . Apart from the usual mechanisms (impaired neutrophil chemotaxis and phagocytosis) by which diabetes predisposes to ...
Ref: Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations [Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020-08-31]Individuals with type 2 diabetes and obesity are commonly prescribed with DPP4 inhibitors and/or GLP-1 receptor analogs.
... Individuals with type 2 diabetes and obesity are commonly prescribed with DPP4 inhibitors and/or GLP-1 receptor analogs. DPP4 inhibitors can be divided in mimetics, sitagliptin, vildagliptin, saxagliptin and not peptide mimetics, alogliptin and linagliptin. DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown ...
Ref: COVID-19 and diabetes: Can DPP4 inhibition play a role? [Diabetes Res Clin Pract, 2020-03-26]DPP4 is well known to diabetes researchers and medical practitioners
... of peptides, chemokines and bioactive compounds, resulting in either inactivation or activation of its substrates. DPP4 is well known to diabetes researchers and medical practitioners because it inactivates the well-studied gut-derived incretins, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) that are ...
Ref: SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? [Immun Ageing, 2020-06-30]There are controversies regarding whether renin-angiotensin system (RAS) inhibition is harmful or protective in COVID- 19[67] .
... There are controversies regarding whether renin-angiotensin system (RAS) inhibition is harmful or protective in COVID- 19[67] . Even though ACE inhibitors and angiotensinreceptor blockers (ARB) do not directly inhibit ACE2 [68] , ACE inhibitors affect the expression of ACE2 in the heart and kidney, and ARB could ...
Ref: Diabetes and COVID-19: Global and Regional Perspectives [Diabetes Res Clin Pract, 2020-07-03]Diabetes has been found to be one of the leading comorbidities associated with fatality in COVID-19 patients.
... BACKGROUND: Diabetes has been found to be one of the leading comorbidities associated with fatality in COVID-19 patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry is facilitated by interaction with Angiotensin Converting Enzyme-2 (ACE2) and possible polymorphisms in ACE2 can be a determining factor in host-viral ...
Ref: COVID-19 and diabetes; Possible role of polymorphism and rise of telemedicine [Diabetes Res Clin Pract, 2020]As my role is in surgery, acute systemic inflammation in people with type two diabetes is always on my mind to improve perioperative glycaemia and outcomes.
... inhibition may play a role in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) treatment 1 . As my role is in surgery, acute systemic inflammation in people with type two diabetes is always on my mind to improve perioperative glycaemia and outcomes. I wanted to add to your discussion based on my experience in this field. ...
Ref: Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? – GLP-1 Might Play One Too [Diabetes Res Clin Pract, 2020-04-22]patients with more comorbidities tend to have more severe disease and worse prognosis, especially in those with diabetes mellitus, cardiovascular disease, and cancers along with elderly.
... likely to widespread. Although COVID-19 has lower fatal rate as compared with SARS-CoV and MERS-CoV, patients with more comorbidities tend to have more severe disease and worse prognosis, especially in those with diabetes mellitus, cardiovascular disease, and cancers along with elderly. 3 The entry routes of different viruses often lead to differences in clinical manifestations and ...
Ref: Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19 [J Chin Med Assoc, 2020-04-29]Under the hypothesis that treatment with DPP4i could prevent COVID-19 progression in subjects with diabetes,
... immunopathogenesis: 1) by altering a potential SARS-CoV-2/DPP4 interaction; 2) by halting disease progression towards hyperinflammation. Under the hypothesis that treatment with DPP4i could prevent COVID-19 progression in subjects with diabetes, the aim of this analysis is to examine the association between DPP4i use among those ...
Ref: Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths [Diabetes Res Clin Pract, 2020-09-16]This may be a dramatic link between COVID-19 and diabetes, because the latter are more susceptible to abnormal coagulation and fibrinolysis,
... diffuse microangiopathy with ischemic and thrombotic lesions that induce alveolar edema and collapse [22] . This may be a dramatic link between COVID-19 and diabetes, because the latter are more susceptible to abnormal coagulation and fibrinolysis, to impaired tissue remodeling and to multiorgan fibrosis and failure [23] [24] [25] [26] [27] ...
Ref: Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 [Acta Diabetol, 2020-06-06]diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19.
... According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many ...
Ref: cord_uid o99mtt0v Diabetes and COVID-19. o99mtt0v Diabetes and COVID-19 Name: title, dtype: object [Acta Diabetol, cord_uid o99mtt0v 2020-05-15 o99mtt0v 2020-05-15 Name: publish_time, dtype: object]Hence the possibility of DPP4 facilitating the entry of SARS CoV-2 into the cell cannot be ruled out.
... receptor for Middle East respiratory syndrome coronavirus responsible for its entry into cell [19] . Hence the possibility of DPP4 facilitating the entry of SARS CoV-2 into the cell cannot be ruled out. In that context, it is an interesting postulation that widespread use of DPP4 inhibitors in ...
Ref: cord_uid 4ti8l2ea Diabetes and COVID-19: evidence, current statu... 4ti8l2ea Diabetes and COVID-19: evidence, current statu... Name: title, dtype: object [Acta Diabetol, cord_uid 4ti8l2ea 2020-05-13 4ti8l2ea 2020-05-13 Name: publish_time, dtype: object]Imbalance of the RAAS and direct effect of soluble DPP4 exert deleterious vascular effects.
... for MERS-CoV. The renin–angiotensin–aldosterone system (RAAS) component ACE2 and DPP4 are proteins dysregulated in diabetes. Imbalance of the RAAS and direct effect of soluble DPP4 exert deleterious vascular effects. We hypothesize that diabetic patients might be more affected by COVID-19 due to increased presence ...
Ref: DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? [Front Pharmacol, 2020-08-07]DPP4 inhibitors improve glycemic control by inhibiting the degradation of GLP-1-a gut hormone secreted by intestinal neuroendocrine cells that stimulates postprandial insulin secretion.
... peptide-1] receptor antagonists) are pharmacological agents used to modulate the incretin pathway of gut hormones. DPP4 inhibitors improve glycemic control by inhibiting the degradation of GLP-1-a gut hormone secreted by intestinal neuroendocrine cells that stimulates postprandial insulin secretion. 76 The GLP-1-RAs are either endogenous or exogenous analogues of GLP-1. Prospective randomized placebo-controlled cardiovascular ...
Ref: COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease [Arterioscler Thromb Vasc Biol, 2020-07-20]DPP4 upregulation may be a determinant of Covid-19 disease severity,
... older individuals and increased plasma DPP4 is a predictor of the onset of metabolic syndrome. DPP4 upregulation may be a determinant of Covid-19 disease severity, which creates interest regarding the use of gliptins in management of Covid-19. Also, knowledge of ...
Ref: Covid-19 and co-morbidities: a role for Dipeptidyl Peptidase 4 (DPP4) in disease severity? [Journal of diabetes, 2020-05-11]however the biological importance of sACE2 remains uncertain.
... DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740), however the biological importance of sACE2 remains uncertain. The extracellular domain of both ACE2 and sACE2 bind SARS-CoV (55), and SARS-CoV-2 (56), raising ...
Ref: Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications [Endocr Rev, 2020-04-15]Though DPP4 inhibitor is preferably safe, its frequency of intake is reduced in this study in individuals with COVID-19.
... the patients continued taking metformin while they were diagnosed with COVID-19 as well as sulfonylurea. Though DPP4 inhibitor is preferably safe, its frequency of intake is reduced in this study in individuals with COVID-19. Among the other drugs that included SGLT2 inhibitors the intake was reduced which is beneficial ...
Ref: Clinical manifestations along with biochemical and psychological outcomes of COVID-19 cases in diabetic individuals in Bangladesh [Endocr Rev, 2020-09-25]Poor-controlled blood glucose levels in diabetes may impair antigen presentation in DCs, resulting in T cell dysfunction.
Poor-controlled blood glucose levels in diabetes may impair antigen presentation in DCs, resulting in T cell dysfunction. Hyperglycemia may also increase inflammatory macrophage population.
Ref: COVID-19 and diabetes: the contributions of hyperglycemia [J Mol Cell Biol, 2020-10-01]Kidney comorbidity as well as hypertension and diabetes mellitus have been suggested as death predictors in coronavirus patients [20, 21] .
... Kidney comorbidity as well as hypertension and diabetes mellitus have been suggested as death predictors in coronavirus patients [20, 21] . According to the high expression values of ACE2, TMPRSS2, CLEC4M, DDP4 and TMPRSS11D in the normal skin compartment indicated in Figure 3 , and the large interactive relationships with skin ...
Ref: An investigation into the molecular basis of cancer comorbidities in coronavirus infection [FEBS Open Bio, 2020-09-24]direct effect of soluble DPP4 exert deleterious vascular effects
... (RAAS) component ACE2 and DPP4 are proteins dysregulated in diabetes Imbalance of the RAAS and direct effect of soluble DPP4 exert deleterious vascular effects We hypothesize that diabetic patients might be more affected by COVID-19 due to increased presence ...
Ref: DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? LID - 1161 [Frontiers in Pharmacology, 2020]DPP4 inhibitors can reduce the risk of acute respiratory complications in type 2 diabetes with COVID-19 infection,
... whether DPP4 has a potential role in COVID-19. So we mustn"t run to presume that DPP4 inhibitors can reduce the risk of acute respiratory complications in type 2 diabetes with COVID-19 infection, and for now we need to distinguish DPP4 inhibition from DPP4 inhibitors until future studies ...
Ref: Letter to the Editor in response to the article “COVID-19 and diabetes: Can DPP4 inhibition play a role?” [Diabetes Res Clin Pract, 2020-04-23]Thus, the combination of DPP4 inhibition and suppression of ACE-2/RAAS may be a novel therapeutic strategy for combating this pandemic.
... peptidase-4 (DPP4, also known as adenosine deaminase complexing protein 2, CD26) as a co-receptor when entering cells. In addition, DPP4 is also implicated in the regulation of the immune response. Thus, the combination of DPP4 inhibition and suppression of ACE-2/RAAS may be a novel therapeutic strategy for combating this pandemic. ...
Ref: A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression [Med. Hypotheses, 2020]Both enzyme expression patterns change in diabetes,
... enzyme 2 (ACE2), while MERS uses dipeptidyl peptidase-IV (DPP4) as its receptor [5, 6] . Both enzyme expression patterns change in diabetes, albeit in different ways, making the receptor proteins themselves an unlikely explanation for the elevated ...
Ref: Diabetes and COVID-19: Disease—Management—People [Wien Klin Wochenschr, 2020-05-20]In addition, DPP4 is also implicated in the regulation of the immune response.
... also known as adenosine deaminase complexing protein 2, CD26) as a co-receptor when entering cells. In addition, DPP4 is also implicated in the regulation of the immune response. Thus, the combination of DPP4 inhibition and suppression of ACE-2/RAAS may be a novel therapeutic ...
Ref: A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression [Med. Hypotheses, 2020]Patients with diabetes are highly susceptible to COVID-19-induced adverse outcomes and complications.
... (COVID-19) pandemic has infected >22.7 million and led to the deaths of 795,000 people worldwide. Patients with diabetes are highly susceptible to COVID-19-induced adverse outcomes and complications. The COVID-19 pandemic is superimposing on the preexisting diabetes pandemic to create large and significantly ...
Ref: cord_uid jpq315hu COVID-19 and Diabetes: A Collision and Collusi... jpq315hu COVID-19 and Diabetes: A Collision and Collusi... Name: title, dtype: object [Med. Hypotheses, cord_uid jpq315hu 2020 jpq315hu 2020 Name: publish_time, dtype: object]Whether the DPP-4 enzyme also plays a role in the association between diabetes and COVID-19 is currently unknown.
... into cells [42] . On the other hand, the DPP-4 enzyme is known to be involved in the immune system and increases inflammation in type 2 diabetes mellitus [43] . Whether the DPP-4 enzyme also plays a role in the association between diabetes and COVID-19 is currently unknown. ...
Ref: Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective [Diabetes Metab J, 2020-06-29]a series of indirect findings suggest that the DPP4 system can have important biological actions beyond glucose metabolism as DPP4 can have a pro-inflammatory action,
... glucagon release. DPP4 rapidly degrades circulating GLP-1 and GIP, thus contributing to glycemic homeostasis. However, a series of indirect findings suggest that the DPP4 system can have important biological actions beyond glucose metabolism as DPP4 can have a pro-inflammatory action, stimulating the production of IL-6 and TNF-α in monocytes, as well as exert a possible ...
Ref: Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring [Intern Emerg Med, 2020-06-26]are known to modify the biological activities of multiple immunomodulatory substrates.
... homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ...
Ref: Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications [Endocr. rev, 2020]there is insufficient evidence either for or against the use of DPP-4i in patients with diabetes and COVID-19 [59] .
... inhibitors have been associated with an increased risk of upper respiratory infections, however these agents have not been shown to lead to increased risk of pneumonia [45] . At present, there is insufficient evidence either for or against the use of DPP-4i in patients with diabetes and COVID-19 [59] . ...
Ref: Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations [Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020-08-31]DPP4, a transmembrane protein, has been identified in human adipose tissue and is associated with obesity-related type 2 diabetes.
... and interacts with T cells and nuclear factors involved in the pathogenesis of inflammatory disorders. DPP4, a transmembrane protein, has been identified in human adipose tissue and is associated with obesity-related type 2 diabetes. DPP4 inhibition increases glucagon like peptide-1 secretion, leading to an improved insulin sensitivity and glucose ...
Ref: Targeting the Adipose Tissue in COVID‐19 [Obesity (Silver Spring), 2020-05-21]DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and nonenzymatic immunomodulatory effects.
... in plasma; it is multifunctional with roles in nutrition, metabolism, and immune and endocrine systems. DPP4 activity differentially regulates glucose homeostasis and inflammation via its enzymatic activity and nonenzymatic immunomodulatory effects. The importance of DPP4 for the medical community has been highlighted by the approval of ...
Ref: cord_uid iml9ig5n COVID-19 and comorbidities: A role for dipepti... iml9ig5n COVID-19 and comorbidities: A role for dipepti... iml9ig5n COVID-19 and comorbidities: A role for dipepti... Name: title, dtype: object [Obesity (Silver Spring), cord_uid iml9ig5n 2020 iml9ig5n 2020 iml9ig5n 2020 Name: publish_time, dtype: object]The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19.
... in several tissues, including but not limited to lung, kidney, liver, gut, and immune cells. The question has been raised on whether DPP4 modulation or inhibition may prevent infection and/or progression of the COVID-19. A docked complex model of the SARS-CoV-2 spike glycoprotein and DPP4 has been proposed, showing ...
Ref: DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19? [Diabetes Metab Res Rev, 2020]Management of diabetes today has been addressed as an exciting confusion [1] .
... Management of diabetes today has been addressed as an exciting confusion [1] . Considering the fast spread of the "Corona Virus Disease 2019 (COVID-19)" due to the "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)", there is currently a considerable debate on several important ...
Ref: COVID-19 and diabetes management: What should be considered? [Diabetes Res Clin Pract, 2020-04-17]Coronavirus receptors were found to be expressed in several body districts.
... analysis, the area under the curve (AUC) was used to discriminate healthy from cancer patients. Coronavirus receptors were found to be expressed in several body districts. Moreover, the five genes were found to associate with acute respiratory syndrome, diabetes, cardiovascular diseases ...
Ref: An investigation into the molecular basis of cancer comorbidities in coronavirus infection [Diabetes Res Clin Pract, 2020]There has been much concern about the pharmacological therapy for diabetic patients with COVID-19.
... There has been much concern about the pharmacological therapy for diabetic patients with COVID-19. Current recommendations for anti-diabetic drugs for diabetic patients with COVID-19 mainly include maintaining previous medication for the mild cases and changing to insulin for regular and severe cases (10) . ...
Ref: Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China [Front Endocrinol (Lausanne), 2020-09-24]Diabetes is a frequent comorbidity in patients with Severe COVID-19 infection associated with a worse prognosis.
... BACKGROUND AND AIMS: Diabetes is a frequent comorbidity in patients with Severe COVID-19 infection associated with a worse prognosis. Hypercoagulability with elevation in D-dimer levels has been demonstrated in patients with COVID-19. This study aims to study D-dimer levels in people with diabetes compared to those ...
Ref: Relation of D-dimer levels of COVID-19 patients with diabetes mellitus [Diabetes Metab Syndr, 2020]it is still unclear whether DPP4 has a potential role in COVID-19.
... are exposed to low grade chronic inflammation [1] which can cause an abnormal immune response, it is still unclear whether DPP4 has a potential role in COVID-19. So we mustn"t run to presume that DPP4 inhibitors can reduce the risk of acute ...
Ref: Letter to the Editor in response to the article “COVID-19 and diabetes: Can DPP4 inhibition play a role?” [Diabetes Res Clin Pract, 2020-04-23]Available data suggest that the issue of CoViD-19 is particularly critical in patients with diabetes.
... Available data suggest that the issue of CoViD-19 is particularly critical in patients with diabetes. In Italy, Internal Medicine (IM) wards have played a pivotal role in contrasting the spread of SARS-Cov2. During this pandemic, FADOI submitted a brief questionnaire to a group of its ...
Ref: Diabetes and CoViD-19: Experience from the frontline of Internal Medicine wards in Italy [Diabetes Res Clin Pract, 2020]DPP4 a transmembrane protein, has been found to be highly expressed in human visceral adipose tissue and is associated with insulin resistance and adipocyte inflammation..
... T cells and nuclear factors such as NF-kβ, involved in the pathogenesis of inflammatory disorders. DPP4 a transmembrane protein, has been found to be highly expressed in human visceral adipose tissue and is associated with insulin resistance and adipocyte inflammation.. DPP-4 inhibition increases glucagon like peptide -1 (GLP-1) secretion leading to an improved insulin sensitivity ...
Ref: SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity [Diabetes Metab Syndr, 2020-07-21]Evidence suggests diabetes to be a risk factor for the progression and poor prognosis of COVID-19.
... and within no time, it has been declared a pandemic by the World Health Organization. Evidence suggests diabetes to be a risk factor for the progression and poor prognosis of COVID-19. Therefore, we aimed to understand the pooled prevalence of diabetes in patients infected with COVID-19. ...
Ref: Burden of diabetes mellitus and its impact on COVID-19 patients: A meta-analysis of real-world evidence [Diabetes Metab Syndr, 2020]Background Association between DPP4 inhibitors and respiratory infection remains unclear.
... Background Association between DPP4 inhibitors and respiratory infection remains unclear. CardioVascular Outcomes Trials (CVOTs) conducted before the COVID-19 pandemic are available. We aimed to estimate the effect of DPP4 inhibitors on the risk of respiratory infections. Methods We updated a ...
Ref: DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19 [Diabetes Metab Syndr, 2020-07-29]Diabetes mellitus is associated with poor prognosis in patients with COVID-19.
... BACKGROUND AND AIMS: Diabetes mellitus is associated with poor prognosis in patients with COVID-19. On the other hand, COVID-19 contributes to worsening of dysglycemia in people with diabetes mellitus over and above that contributed by stress hyperglycemia. Herein, we have reviewed ...
Ref: COVID-19 and diabetes mellitus: An unholy interaction of two pandemics [Diabetes Metab Syndr, 2020]Individuals with diabetes are at a greater risk of hospitalization and mortality resulting from viral, bacterial and fungal infections.
... Abstract Background Individuals with diabetes are at a greater risk of hospitalization and mortality resulting from viral, bacterial and fungal infections. The Coronavirus Disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread quickly to more than 213 countries across the world and has claimed 395,779 lives ...
Ref: Diabetes, Infection Risk And Covid-19 [Mol Metab, 2020-06-23]it has been found to be involved in pathomechanisms of various processes, including inflammation, angiogenesis, and carcinogenesis.
... DPP4 is widely expressed on the surface of various cell types, including respiratory epithelia. Noteworthy, although DPP4 was initially studied mainly in the context of adipose tissue, obesity, and diabetes, it has been found to be involved in pathomechanisms of various processes, including inflammation, angiogenesis, and carcinogenesis. ...
Ref: Do novel drugs for diabetes help in COVID‐19? Another brick in the wall? [J Diabetes, 2020-05-22]Diabetic medications do not seem to have either protective or detrimental effect on COVID-19 incidence and severity;
... and cases of COVID-19-induced diabetes 9 were not classified as diabetes in the present database. Diabetic medications do not seem to have either protective or detrimental effect on COVID-19 incidence and severity; in particular, we found no effect of DPP4-inhibitors, which were previously highlighted as possible Covid-19 ...
Ref: Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily [Nutr Metab Cardiovasc Dis, 2020-10-01]DPP4 is currently used to treat type 2 diabetes by targeting the incretin system.
... DPP4 is currently used to treat type 2 diabetes by targeting the incretin system. Recently, it was hypothesised that individuals on DPP4 may demonstrate a reduction in the severity of SARS-CoV-2 [35] . Yet, this is based on preclinical data and so caution must ...
Ref: COVID-19 and diabetes: The why, the what and the how [J Diabetes Complications, 2020-05-22]Diabetes has been identified as a pre-existing health condition linked with worse outcomes following coronavirus disease 2019 infection.
... Diabetes has been identified as a pre-existing health condition linked with worse outcomes following coronavirus disease 2019 infection. Here we explore the association between hyperglycaemia and more severe illness, the impact of the pandemic on diabetes service delivery, and the resultant opportunities for innovation. ...
Ref: COVID-19: Impact of and on Diabetes [Diabetes Ther, 2020-06-06]may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection,
... generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood ...
Ref: Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis [Int. j. environ. res. public health (Online), 2020]DPP4 enzyme is a type II transmembrane glycoprotein, expressed ubiquitously in many tissues, including the immune cells.
... DPP4 enzyme is a type II transmembrane glycoprotein, expressed ubiquitously in many tissues, including the immune cells. Although its functions are not fully understood yet, DPP4 plays a major role in glucose and insulin metabolism. DPP4 degrades incretins such as glucagon like peptide 1 (GLP-1) and glucose-dependent ...
Ref: COVID-19 and diabetes: Can DPP4 inhibition play a role? [Diabetes Res Clin Pract, 2020-03-26]Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections.
... Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 ...
Ref: Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications [Endocr. rev, 2020]a DPP4-mediated immune dysregulation could result in higher rates of mortality and complications in diabetic patients.
... patients. This is based on the belief and earlier observations in MERS-COV-infected diabetic patients that a DPP4-mediated immune dysregulation could result in higher rates of mortality and complications in diabetic patients. However, there is no direct evidence so far that the same is true of COVID-19 ...
Ref: Post COVID-19 diabetes care—lessons and challenges [Int J Diabetes Dev Ctries, 2020-06-04]The literature surrounding the association between cardiovascular disease (CVD) and diabetes mellitus (DM) with SARS-CoV-2 is sparse.
... The literature surrounding the association between cardiovascular disease (CVD) and diabetes mellitus (DM) with SARS-CoV-2 is sparse. Roy et al. propose multiple pathways to explain these complex relationships. There are two aspects pertaining to CVD; firstly, the concept that SARS-CoV-2 can propagate the development of CVD, and ...
Ref: Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection [SN Compr Clin Med, 2020-08-17]DPP4 is a transmembrane glycoprotein expressed in many tissues, including immune cells.
... DPP4 is a transmembrane glycoprotein expressed in many tissues, including immune cells. It activates T cells, upregulates CD86 expression on macrophages and B cells, and stimulates the NF-jb pathway, thereby promoting inflammation. Moreover, DPP4 was found to be the same as CD26, ...
Ref: Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature [Adv Ther, 2020-07-06]Individuals with diabetes are at a greater risk of hospitalization and mortality resulting from viral, bacterial, and fungal infections.
... BACKGROUND: Individuals with diabetes are at a greater risk of hospitalization and mortality resulting from viral, bacterial, and fungal infections. The coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread quickly to more than 213 countries and claimed 395,779 lives as of June 7, 2020. ...
Ref: Diabetes, infection risk and COVID-19 [Mol Metab, 2020]One of the most distinctive co-morbidities is diabetes mellitus [6] .
... prevalent co-morbidities increase the severity and mortality of COVID-19 [14, 27, [39] [40] [41] . One of the most distinctive co-morbidities is diabetes mellitus [6] . Out of 1099 cases reported by Guan et al., 16 .2% of patients with severe ...
Ref: Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19 [Cells, 2020-06-02]T2DM is a risk factor for worse prognosis in patients with COVID-19.
... T2DM is a risk factor for worse prognosis in patients with COVID-19. In patients with T2DM, with or without COVID-19, the goal should remain to achieve an optimal glycemic control and minimize the risk for hypoglycemia and related risk for hospitalization. ...
Ref: Managing Type 2 Diabetes Mellitus during COVID‐19 Pandemic: The Bittersweet [Diabetes Metab Res Rev, 2020-06-03]has been widely used to control the glycemic condition in patients with diabetes.
... severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 ...
Ref: cord_uid wxhpo17g Role of dipeptidyl peptidase-4 inhibitors in p... wxhpo17g Role of dipeptidyl peptidase-4 inhibitors in p... Name: title, dtype: object [Diabetes Metab Res Rev, cord_uid wxhpo17g 2020 wxhpo17g 2020 Name: publish_time, dtype: object]may offer a simple way to reduce the virus entry and replication into the airways
... inhibitors, such as gliptins, in patients with COVID-19 with, or even without, type 2 diabetes, may offer a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed ...
Ref: Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 [Acta Diabetol, 2020]The COVID-19 pandemic has added an enormous toll to the existing challenge of diabetes care world-wide.
... The COVID-19 pandemic has added an enormous toll to the existing challenge of diabetes care world-wide. A large proportion of patients with COVID-19 requiring hospitalization and/or succumbing to the disease have had diabetes and other chronic conditions as underlying risk factors. In particular, individuals belonging to ...
Ref: COVID-19 in people living with diabetes: An international consensus [J Diabetes Complications, 2020]The COVID-19 pandemic has challenged both institutional and self-management of diabetes.
... BACKGROUND AND AIMS: The COVID-19 pandemic has challenged both institutional and self-management of diabetes. The ongoing social distancing and lock downs have negatively impacted to access to care and self-management. METHODS: This is a narrative review of diabetes management in a ...
Ref: Self- management of diabetes mellitus during the Covid-19 pandemic: Recommendations for a resource limited setting [Diabetes Metab Syndr, 2020]Patients with diabetes who get coronavirus disease 2019 (COVID-19) are at risk of a severe disease course and mortality.
... Patients with diabetes who get coronavirus disease 2019 (COVID-19) are at risk of a severe disease course and mortality. Several factors especially the impaired immune response, heightened inflammatory response and hypercoagulable state contribute to the increased disease severity. However, there are many contentious issues about which the evidence is ...
Ref: Diabetes and COVID-19: evidence, current status and unanswered research questions [Eur J Clin Nutr, 2020]In recent years, the role of DPP4 in chronic inflammation has been proved.
... In recent years, the role of DPP4 in chronic inflammation has been proved. DPP4 or CD26 is a glycoprotein on the cell surface with 110-kDa molecular weight [20] . DPP4 activity has been shown in mice, rats, and humans and is present in ...
Ref: Inflammation: A bridge between Diabetes and COVID-19, and possible management with sitagliptin [Med Hypotheses, 2020-07-15]High prevalence of diabetes makes it an important comorbidity in patients with COVID-19.
... BACKGROUND AND AIMS: High prevalence of diabetes makes it an important comorbidity in patients with COVID-19. We sought to review and analyze the data regarding the association between diabetes and COVID-19, pathophysiology of the disease in diabetes and management of patients with diabetes ...
Ref: Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations [Diabetes Metab Syndr, 2020]COVID-19 morbidity and mortality are increased in patients with diabetes and kidney disease via unknown mechanisms.
... COVID-19 morbidity and mortality are increased in patients with diabetes and kidney disease via unknown mechanisms. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Since ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease and medications alter ACE2 receptor ...
Ref: SARS-CoV-2 receptor networks in diabetic and COVID-19 associated kidney disease [Kidney Int, 2020-10-08]The DPP4 family/system was implicated in various physiological processes and diseases of the immune system,
... those cells targeted by different human coronaviruses and that clinical complications may be similar. RESULTS: The DPP4 family/system was implicated in various physiological processes and diseases of the immune system, and DPP4/CD26 is variously expressed on epithelia and endothelia of the systemic vasculature, lung, kidney, ...
Ref: Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 [Acta Diabetol, 2020]discussions about those drugs that may be related to infectious condition of COVID-19 diseases.
... to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases. ...
Ref: cord_uid wxhpo17g Role of dipeptidyl peptidase-4 inhibitors in p... wxhpo17g Role of dipeptidyl peptidase-4 inhibitors in p... Name: title, dtype: object [Acta Diabetol, cord_uid wxhpo17g 2020 wxhpo17g 2020 Name: publish_time, dtype: object]are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis.
... 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are ...
Ref: Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications [Endocr. rev, 2020]DPP4 mRNA and protein expressions are significantly higher in smokers compared with never smokers without airflow limitation and are inversely correlated with lung function.
... DPP4 mRNA and protein expressions are significantly higher in smokers compared with never smokers without airflow limitation and are inversely correlated with lung function. 13 It has recently been reported that ACE2 gene expression is higher in ever smokers (both current and former) compared with never smokers in normal lung tissue in a sample ...
Ref: COVID-19 and Smoking [Nicotine Tob Res, 2020-04-03]A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection.
... A possible association could exist between type 2 diabetes mellitus (T2DM) and Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high prevalence, severity of disease and mortality during Covid-19 infection. However, the rates of severe disease are significantly higher in patients with diabetes compared with ...
Ref: Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 [Cardiovasc Diabetol, 2020]Diabetes mellitus may be associated with increased severity and enhanced mortality in COVID-19 infections.
... Background: Diabetes mellitus may be associated with increased severity and enhanced mortality in COVID-19 infections. The present study was undertaken to evaluate the clinical presentation, laboratory parameters, radiological imaging, management, and outcome of COVID-19 infection in patients of diabetes mellitus and its association with ...
Ref: Impact of glycemic control in diabetes mellitus on management of COVID-19 infection [Int J Diabetes Dev Ctries, 2020]Hyperglycemia with or without blood glucose in diabetes range is an emerging finding not uncommonly encountered in patients with COVID-19.
... Hyperglycemia with or without blood glucose in diabetes range is an emerging finding not uncommonly encountered in patients with COVID-19. Increasingly, all evidence currently available hints that both new-onset hyperglycemia without diabetes and new-onset diabetes in COVID-19 is associated with a poorer outcome compared with normoglycemic individuals and people with ...
Ref: Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19 [Diabetes Res Clin Pract, 2020]By employing protein docking strategy, we investigated the potential interaction 144 mode between SARS-CoV-2-S RBD and DPP4.
... By employing protein docking strategy, we investigated the potential interaction 144 mode between SARS-CoV-2-S RBD and DPP4. The atomic interaction details of the 145 binding interface showed that almost all of the contacting residues of DPP4 with 146 SARS-CoV-2-S RBD were consistent with those for binding with ...
Ref: cord_uid 1xf2sxtv The MERS-CoV Receptor DPP4 as a Candidate Bind... 1xf2sxtv The MERS-CoV receptor DPP4 as a candidate bind... Name: title, dtype: object [Diabetes Res Clin Pract, cord_uid 1xf2sxtv 2020-05-13 1xf2sxtv 2020-05-13 Name: publish_time, dtype: object]People with diabetes have multiple psychosocial issues related to diabetes and its complications and this may be exacerbated during the COVID-19 pandemic.
... BACKGROUND AND AIMS: People with diabetes have multiple psychosocial issues related to diabetes and its complications and this may be exacerbated during the COVID-19 pandemic. METHODS: We reviewed the psychological adaptative difficulties in people with diabetes especially during natural disasters including the prevailing COVID-19 pandemic. RESULTS: There are significant concerns regarding worsening ...
Ref: Psychological adaptive difficulties and their management during COVID-19 pandemic in people with diabetes mellitus [Diabetes Metab Syndr, 2020]Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients.
... the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic ...
Ref: Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies [Cardiovasc Diabetol, 2020]According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19.
... According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many research data on antidiabetic ...
Ref: cord_uid 02ua1qyj Diabetes and COVID-19 02ua1qyj Diabetes and COVID-19 Name: title, dtype: object [Cardiovasc Diabetol, cord_uid 02ua1qyj 2020 02ua1qyj 2020 Name: publish_time, dtype: object]DPP4i may hold additional therapeutic value to protect diabetic patients suffering COVID-19,
... preservation of vascular integrity might be a key priority. In case DPP4 represents a link between diabetes and the severity of COVID-19, DPP4i may hold additional therapeutic value to protect diabetic patients suffering COVID-19, as recently especulated (Drucker, 2020; Iacobellis, 2020) . ...
Ref: DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? [Front Pharmacol, 2020-08-07]